Trial Profile
A Randomized, Multicenter Phase III Clinical Trial Comparing Gemcitabine and Cisplatin With 5-Fluorouracil and Cisplatin in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Cisplatin; Fluorouracil
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- 11 Aug 2021 Primary endpoint has been met (Progression free survival (PFS) assessed by independent image committee and the investigators) , according to Results published in the Journal of Clinical Oncology
- 11 Aug 2021 Results reporting data from final overall survival analysis published in the Journal of Clinical Oncology
- 31 May 2020 Status changed from active, no longer recruiting to completed according to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.